We aimed to establish the prevalence of human immunodeficiency virus (HIV)-associated malignancies in children attending a care and treatment clinic at Kilimanjaro Christian Medical Centre.
This was a retrospective cross-sectional hospital-based study of children who attended an HIV care and treatment clinic between 2006 and 2014. Children aged 2 months to 17 years were eligible for participation. The data on social demographic and clinical characteristics were extracted from the medical record. A multivariate logistic regression model was developed to determine predictors of HIV-associated malignancies.
Medical records from 721 HIV-infected children were reviewed. The median age (interquartile range) at HIV diagnosis was 5.7 (2.0 to 9.4) years. Among them, 34 (4.7%) had HIV-associated malignancies. The most common (n=24, 70.3%) malignancy was the Kaposi sarcoma. Age at HIV diagnosis was significantly associated with HIV-associated malignancies (adjusted odds ratio, 1.2; 95% confidence interval, 1.0-1.3). Among 34 patients with HIV-associated malignancies, 11 (32.4%) died. Seven (20.6%) patients reported complete remission from their malignancies, and outcomes for 6 patients were unknown.
The prevalence of HIV-associated malignancies was high and was associated with late HIV diagnosis. The Kaposi sarcoma was the commonest malignancy. Early HIV diagnosis and treatment in children might reduce HIV-associated malignancies.
*Kilimanjaro Christian Medical University College
†Kilimanjaro Christian Medical Centre
‡Kilimanjaro Clinical Research Institute, Moshi, Tanzania
§Duke Global Health Institute, Duke University, NC
Study was supported by the HIV-Associated Malignancy Training Research Program (HAMTRP) (Grant D43CA153722) as part of its mentored research training program. J.B. is supported by P30AI064518, D43TW00959, and D43TW010138.
The authors declare no conflict of interest.
Reprints: James S. Ngocho, MSc, Kilimanjaro Christian Medical University College, P.O. Box 2240, Moshi, Tanzania (e-mail: email@example.com).
Received May 14, 2018
Accepted November 18, 2018